Additional file 1 of Eligibility of real-world patients for aspirin primary prevention trials in cardiovascular disease

Figshare 2026 Open access

Read full text
Authors: M. Holder, Daniel R. Morales, Peter Hanlon, David McAllister, Bruce Guthrie
DOI: 10.6084/m9.figshare.31199258
Cited by: 0

Abstract

Additional file 1. Tables S1–S19. Table S1 Trial characteristics. Tables S2–S15 Eligibility criteria for each of the 14 trials. Table S16 Differences between trial-eligible, trial-ineligible, and trial participants. Table S17 Differences between trial-eligible and trial-ineligible for each of the 14 trials. Table S18 Hazards of MACE and bleeding events. Table S19 Time-varying hazards of non-CVD death.

Fields of Study & Subjects

Antiplatelet Therapy and Cardiovascular Diseases Lipoproteins and Cardiovascular Health Inflammatory mediators and NSAID effects

Publication details

Journal / source
Figshare
Publication date
1 January 2026